Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes

Bibliography

• SALEH YM, MUDALIAR SR, HENRY, RR: Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Rev. (1999) 7:55–76.
   Google Scholar
• LEBOVITZ HE: a-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. (1998) 6:132–145.
   Google Scholar
• CUSI K, DEFRONZO RA: Metformin: a review of its metabolic effects. Diabetes Rev. (1998) 6:89–131.
   Google Scholar
• PERFETTI R, BARNETT PS, MATHUR R, EGAN JM: Novel therapeutic strategies for the treatment of type 2 diabetes. Diabetes Metab. Rev. (1998) 14:207–25.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN BR, HAGEN MD: An evaluation of new agents in the treatment of type 2 diabetes. J. Farm Pract. (1998) 47 (Suppl. 5):S37–43.
   Google Scholar
• SCHNEIDER R, LESSEM J, LEKICH R: Pioglitazone 011 Study Group: Pioglitazone is effective in the treatment of patients with type 2 diabetes. Diabetes (1999) 48\(Suppl. 1):A109.
   Google Scholar
• MATHISEN A, GEERLOF J, HOUSER V: Pioglitazone 026 Study Group: The effect of Pioglitazone on glucose control and lipid profile in patients with type 2 diabetes (T2D). Diabetes (1999) 48\(Suppl. 1):A102.
   Google Scholar
• GRUNBERGER G, WESTON WM, PATWARDHAN R, RAPPAPORT EB: Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes (T2D). Diabetes (1999) 48\(Suppl. 1):A102.
   Google Scholar
• RASKIN P, RAPPAPORT EB: Rosiglitazone (RSG) improves fasting and postprandial plasma glucose in type 2 diabetes. Diabetes (1999) 48\(Suppl. 1):A95.
   Google Scholar
• AMOS AF, MCCARTY DJ, ZIMMET P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. DiabeL Med. (1997) 14\(Suppl. 5):S1–85.
   Google Scholar
• REAVEN GM: Pathophysiology of insulin resistance in human disease. Physiol. Rev. (1995) 75:473–486.
   PubMed Web of Science ®Google Scholar
• REAVEN GM, LITHELL H, LANDSBERG L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New Engl. J. Med. (1996) 334:374–381.
   PubMed Web of Science ®Google Scholar
• •Describes the interrelation between the sympathoadrenal system and diabetes/hypertension.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E, ORCHARD T: Diabetes and heart disease. In: Diabetes in America. NIH Pub!. No. 85–1468. National Diabetes Data Group, Department of Health and Human Services, Washington, D.C. (1984):P-XVI–1–41
   Google Scholar
• ELKELES RS et al: Cardiovascular outcomes in type 2 diabetes: A double-blindplacebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabet. Care (1998) 21:641–648.
   PubMed Web of Science ®Google Scholar
• CINCOTTA AH, SCHILLER BC, MEIER AH: Bromocriptine inhibits the seasonally occurring obesity, hyperinsu-linemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism (1991) 40:639–644.
   PubMed Web of Science ®Google Scholar
• CINCOTTA AH, MACEACHERN TA, MEIER AH: Bromocriptine redirects metabolism and prevents seasonal onset of obese hyerinsulinemic state of Syrian hamster. Am. J. Physiol (1993) 264:E285–E293.
   PubMed Web of Science ®Google Scholar
• •Describes the effects of bromocriptine on lipid mobilisation and FFA.
   Google Scholar
• CINCOTTA AH, MEIER AH: Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism (1995) 44:1349–1355.
   PubMed Web of Science ®Google Scholar
• •Describes the effects of bromocriptine on hepatic glucose output.
   Google Scholar
• MEIER H, CINCOTTA AH: Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev. (1996) 4:464–487.
   Google Scholar
• ••Reviews circadian neuroendocrine regulation ofmetabolism.
   Google Scholar
• CINCOTTA AH, WILSON JM, DESOUZA CJ, MEIER AH: Properly timed injections of cortisol and prolactin produce long-term reductions in obesity, hyperinsu-linemia and insulin resistance in the Syrian hamster (Mesocricetus auratus). J. Endocrinol. (1989) 120:385–391.
   PubMed Web of Science ®Google Scholar
• CINCOTTA AH, SCHILLER BC, LANDRY RJ: Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat. Chronobiol. Int. (1993) 10:244–258.
   PubMed Web of Science ®Google Scholar
• UTRICHARD DC: Multiple CNS receptor interactions of ergot alkaloids: affinity and intrinsic activity analysis in in-vitro binding systems. In: Ergot Compounds, and Brain Functions; Neuroendocrine and Neuropyschiatric Aspects. Goldstein M, Lieberman A, Caine DB, Thorner MO (Eds.), Raven Press, New York, (1980):103–116.
   Google Scholar
• LUO S, LIANG Y, CINCOTTA AH: Intracerebroven-tricular administration of bromocriptine ameliorates the insulin resistant/glucose intolerant state in hamsters. Neuroendocrinology (1999) 69:160–166.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates the central effect of bromocriptine onmetabolism.
   Google Scholar
• LUO S, MEIER AH, CINCOTTA AH: Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinolgy (1998) 68:1–10.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates differences in VMH norepinephrine andserotonin metabolism of glucose tolerant versus intolerant animals and the bromocriptine effect therein.
   Google Scholar
• LUO S, LUO J, CINCOTTA AH: Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology (1999) (In Press).
   Google Scholar
• ••Describes the effect of chronic VMH norepinephrineinfusion to induce glucose intolerance in hamsters.
   Google Scholar
• DEFRONZO RA, BONADONNA RC, FERANNINI E: Pathogenesis of NIDDM. Diabetes Care (1992) 15:318–368.
   PubMed Web of Science ®Google Scholar
• CONSOLI A: Role of liver in pathophysiology of NIDDM. Diabetes Care (1992) 15:430–441.
   PubMed Web of Science ®Google Scholar
• ••Discusses the major role of hepatic glucose output tocontribute to the hyperglycaemia of type 2 diabetes.
   Google Scholar
• REAVEN GM: The fourth musketeer - from AlexandreDumas to Claude Bernard. Diabetologia (1995) 38:3–13.
   PubMed Web of Science ®Google Scholar
• BODEN G: Fatty acids and insulin resistance. DiabetesCare (1996) 19:394–395.
   Google Scholar
• KRUSZYNSKA YT, MULFORD MI, YU JG, ARMSTRONG DA:Effects of nonesterifled fatty acids on glucose metabo-lism after glucose ingestion. Diabetes (1997) 46:1586–1593.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB MS: Diabetes in offspring and siblings ofjuvenile- and maturity-onset type diabetics. J. Chronic Disease (1980) 33:331–339.
   PubMedGoogle Scholar
• SAKUL H, PRATLEY R, CARDON L, RAVUSSIN E, MOTT D, BOGARDUS C: Familiality of physical and metabolic characteristics that predict the development of non-insulin dependent diabetes mellitus in Pima Indians. Am. J. Human Genet. (1997) 60: 651–656.
   PubMed Web of Science ®Google Scholar
• THEN BERG H: The genetic aspects of diabetes mellitus. JAMA (1939) 112:1091.
   Google Scholar
• BARNETT AH, EFF C, LESLIE RD, PYKE DA: Diabetes in identical twins. Diabetologia (1981) 20:87–93.
   PubMed Web of Science ®Google Scholar
• NEWMAN B, SELBY JV, KING MC, SLEMENDA C, FABSITZ R, FRIEDMAN GD: Concordance for type 2 (non-insulin dependent) diabetes mellitus in male twins. Diabetologia (1987) 30:763–768.
   PubMed Web of Science ®Google Scholar
• WARRAM JH, RICH SS, KROLEWSKI AS: Epidemiology and genetics of diabetes mellitus. In: Joslin' Diabetes Mellitus. Kahn CWG (Ed.), Lea & Febiger, Philadelphia (1995):201–215.
   Google Scholar
• KAHN CR: Insulin action, diabetogenes, and the cause of Type II diabetes (Banting Lecture). Diabetes (1994) 43:1066–1064.
   PubMed Web of Science ®Google Scholar
• PERMUTT MA: Genetics of NIDDM. Diabetes Care (1990)13:1150–1153.
   PubMed Web of Science ®Google Scholar
• TURNER RC, EVY JC, CLARK A: Complex genetics of type 2 diabetes: thrifty genes and previously natural polymorphisms. Quarterly J. Med. (1993) 86:413–417.
   PubMedGoogle Scholar
• ZIMMETT P: Challenges in diabetes epidemiology - from West to the rest. Diabetes Care (1992) 15:232–252.
   PubMed Web of Science ®Google Scholar
• WEISS KM, FERREL RE, HANIS CL: A new world syndrome of metabolic diseases with a genetic and evolutionary basis. Yearbook Physical Anthropol. (1984) 27:153–178.
   Web of Science ®Google Scholar
• DOWSE G, ZIMMETT P: The thrifty genotype in non-insulin dependent diabetes. Br. Med. J. (1993) 306:532–533.
   PubMed Web of Science ®Google Scholar
• NEEL JV: Diabetes mellitus: a thrifty genotype rendereddetrimental by progress? Am. J. Human Genet. (1996) 14:353–362.
   Google Scholar
• NEEL JV: The Thrifty Genotype Revisited. In: The Genetics of Diabetes Mellitus. Kobberling J, Tattersall R (Eds.), Academic Press, London (1998):283–293.
   Google Scholar
• GOLAY A, FELBER JP, MEYER HU, CURCHOD B, MAEDER E, JEQUIER E: Study on lipid metabolism in obesity diabetes. Metabolism (1984) 33:111–116.
   PubMed Web of Science ®Google Scholar
• GROOP LC, BONNADONNA RC, SIMONSON DC, PETRIDES AS, SHANK M, DEFRONZO R: Effects of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity. Am. J. Physiol. (1992) 263:E79–E84.
   PubMed Web of Science ®Google Scholar
• SCHULZ Y, TREMBLAY A, WEINSIER RL, NELSON KM: Roleof fat oxidation in the long-term stabilization of body weight in obese women. Am. J. Clin. Nutr. (1992) 55:670–674.
   PubMed Web of Science ®Google Scholar
• BODEN G. CHEN X, RUIZ J, WHITE JV, ROSSETTI L: Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. (1994) 94:2349–2356.
   PubMed Web of Science ®Google Scholar
• BEVILACQUA S, DONNADONNA S, BUSSIGLIOLI G et al.: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism (1987) 36:502–506.
   PubMed Web of Science ®Google Scholar
• GROOP LC, SALORANTA C, SHANK M, BONNADONNA RC, FERRANNINI E, DEFRONZO R: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obese subjects. J. Clin. Endocrinol. Metab. (1991) 72:96–107.
   PubMed Web of Science ®Google Scholar
• FELBER JP, FERRANNINI E, GOLAY A et al.: Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes (1987) 36:1341–1350.
   PubMed Web of Science ®Google Scholar
• KRUSZYNSKA YT: The role of fatty acid metabolism in the hypertriglyceridemia and insulin resistance of type 2 (non-insulin dependent) diabetics. Diabetes Ann. (1995) 9:107–139
   Google Scholar
• KRUSZYNSKA YT, MULFORD MI, YU JG, ARMSTRONG DA, OLEFSKY JO: Effects of nonesterifled fatty acids on glucose metabolism after glucose ingestion. Diabetes (1997) 46:1593.
   Web of Science ®Google Scholar
• GOMEZ F, JEQUIER EC, BUBER V, FELBER JP: Carbohy-drate and lipid oxidation in normal human subjects: its influence on glucose tolerance and insulin response to glucose. Metabolism (1972) 21:381–391.
   PubMed Web of Science ®Google Scholar
• CINCOTTA AH, MEIER AH: Reductions of body fat stores and total plasma cholesterol and triglyceride concen-trations in several species by bromocriptine treatment. Life ScL (1989) 45:2247–2254.
   PubMed Web of Science ®Google Scholar
• CAREY RM, VAN LOUN GR, BAINES AD, KAISER DL: Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J. Clin. Endocrinol. Metab. (1983) 56:595–602.
   PubMed Web of Science ®Google Scholar
• ZIEGLER MG, LAKE CR, WILLIAMS AC, TEYCHENNE PF,SHOULSON I, STEINSLAND OS: Bromocriptine inhibits norepinephrine release. Clin. Pharmacol. Ther. (1979) 25:137–142.
   PubMed Web of Science ®Google Scholar
• MANNELLI M, DELATALI G, DE FEO ML et al.: Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. J. Clin. Endocrinol. Metab. (1984) 59:74–78.
   Google Scholar
• REAVEN GR, LITHELL H, LANDSBERG L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New Engl. J. Merl. (1996):374.
   PubMed Web of Science ®Google Scholar
• SCHERRER W, OWLYA RI, LEPORI M: Body fat and sympathetic nerve activity. Cardiovasc. Drugs Ther. (1996) 10:215–222.
   PubMed Web of Science ®Google Scholar
• ••Describes the positive correlation between body fat andsympathetic activity.
   Google Scholar
• GRASSI G, CATTANEO BM, SERAVALLE G, COLOMBO M, CAVAGNINI F, MANCIA G: Obesity and the sympathetic nervous system. Blood Press Suppl. (1996) 1:43–46.
   PubMedGoogle Scholar
• •Describes the positive correlation between body fat and sympathetic activity.
   Google Scholar
• VILA E, BADIA E, JANE F: Effects of bromocriptine oncatecholamine receptors mediating cardiovascular responses in the pithed rat. J. Auton Pharmacol. (1985) 5:125–130.
   PubMedGoogle Scholar
• GIBSON A, SAMINI M: Bromocriptine is a potent f128 a f255 1-adrenoceptor antagonist in the perfused mesenteric blood vessels of the rat. J. Pharm. Pharmacol. (1978) 30:314–315.
   PubMed Web of Science ®Google Scholar
• LEW JY, HATA F, OHASHI T, GOLDSTEIN M: The interac-tions of bromocriptine and lergotrile with dopamine and al-adrenergic receptors. J. Neural Transm. (1977) 41:109–121.
   PubMed Web of Science ®Google Scholar
• FROHMAN LA: Hypothalamic control of metabolism.In: Handbook of the hypothalamus 2, Physiology of the Hypothalamus. Morgane PJ, Panksepp J, (Eds.), Marcel Dekker, New York; (1980):519–555.
   Google Scholar
• LUITEN PGM, TER HORST JG, STEFFENS AB: The hypothalamus, intrinsic connections and outflow pathways to the endocrine system in relation to the control of feeding and metabolism. Prog. Neurobiol. (1987) 28:1–54.
   PubMed Web of Science ®Google Scholar
• JANSEN ASP, NGUYEN XV, KARPITSKIY V, METENLEITERTC, LOEWY AD: Central command neurons of the sympathetic nervous system: basis of the fight or flight response. Science (1995) 270:644–646.
   PubMed Web of Science ®Google Scholar
• BENZO C: The hypothalamus and blood glucose regulation. Life ScL (1983) 32:2509–2515.
   PubMed Web of Science ®Google Scholar
• BORG WP, SHERWIN RS, DURING MJ, SHULMAN GI: Localventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes (1995) 44:180–184.
   PubMed Web of Science ®Google Scholar
• BORG MA, SHERWIN RS, BORG WP, TAMBORLANE WV,SHULMAN GI: Local ventromedial hypothalamus glucose perfusion blocks counterregulation during dystemic hypoglycemia in awake rats. J. Clin. Invest. (1997) 99:361–365.
   PubMed Web of Science ®Google Scholar
• •Discusses the VMH regulation of the counter-regulatory glucose response and hepatic glucose output.
   Google Scholar
• DE JONG A, STRUBBE JH, STEFFENS AB: Hypothalamicinfluence on insulin and glucagon release in the rat. Am. J. Physiol. (1977) 223:E380–E388.
   Google Scholar
• STEFFENS AB, DAMSMA G, VAN DER GUGTEN J: Circulating free fatty acids, insulin, and glucose during chemical stimulation of hypothalamus in rats. Am. J. Physiol (1984) 247:E765–E771.
   PubMed Web of Science ®Google Scholar
• •Describes the acute effect of VMH norepinephrine on plasma glucose, insulin, and glucagon.
   Google Scholar
• SHIMAZU T: Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes/Metab. Rev. (1987) 3:185–206.
   PubMedGoogle Scholar
• •Reviews the VMH regulation of hepatic glucose output.
   Google Scholar
• SUZUKI M, MATSUDA T, ASANO S, SOMBOONTHUM P, TAKUMA K, BABA A: Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine 1A-receptor activation. Br. J. Pharmacol. (1995) 115:703–711.
   PubMed Web of Science ®Google Scholar
• NONOGAKI K, IGUCHI A: Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci. (1997) 60:797–807.
   PubMed Web of Science ®Google Scholar
• SUZUKI M. MATSUDA T, ASANO S. SOMBOONTHUM P, TAKUMA K, BABA A: Increase of noradrenaline release in the hypothalamus of freely moving rats by postsynaptic 5-hydroxytryptaminela receptor activa-tion. Br. J. Pharmacol. (1995) 115:703–711.
   PubMed Web of Science ®Google Scholar
• LIN MT, SHIAN LR: Stimulation of 5-hydroxytryptamine nerve cells in dorsal and median raphe nuclei elevates blood glucose in rats. Eur. Pharm. (1991) 417:441–445.
   Web of Science ®Google Scholar
• LUO S, HODGE S, CINCOTTA AH: Increased daily turnover of noradrenaline and serotonin in the ventral medial hypothalamus (VMH) of obese versus lean Zucker rats assessed by in vivo microdialysis. Society for Neuroscience Abstracts (1996) 22:605.
   Google Scholar
• JONES AP, POTHOS EN, RADA P, OLSTER DH, HOEBEL BG: Maternal hormonal manipulations in rats cause obesity and increase medial hypothalamic norepi-nephrine release in male offspring. Dev. Brain Res. (1995) 88:127–131.
   PubMedGoogle Scholar
• GARRIS DR: Age- and diabetes-associated alterations in regional brain norepinephrine concentrations and adrenergic receptor populations in C57BL/KsJ mice. Dev. Brain Res. (1989) 51:161–166.
   Google Scholar
• OLTMANS GA: Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res. (1983) 273:369–373.
   PubMed Web of Science ®Google Scholar
• KRASZEWSKI K, CINCOTTA AH: Effect of monoamine iontophoresis on neuronal activity in ventromedial hypothalamus of lean and obese mice. Society for Neuroscience Abstracts (1997) 23:1794.
   Google Scholar
• BOUNDY V, CINCOTTA AH: Hypothalamic adrenergic receptor changes in the metabolic syndrome of ob/ob mice. Diabetes (1999) 48\(Suppl. 1):A285.
   Google Scholar
• CINCOTTA AH, LUO S, ZHANG Y, HETTON TL, SEISLOWSKI WD: Chronic infusion of norepinephrine (NE) into the ventromedial hypothalamus (VMH) of normal rats induces the metabolic syndrome. Diabetes (1999) 48\(Suppl. 1):A315.
   Google Scholar
• ••Demonstrates the effects of chronic VMH norepinephrineinfusion on glucose and lipid metabolism to induce the metabolic syndrome.
   Google Scholar
• LUO S, BINA KG, LUO J. CINCOTTA AH: The anti-obesity effects of bromocriptine are associated with altered circadian neuroendocrine rhythms in the Syrian hamster. Society for Neuroscience Abstract (1997).
   Google Scholar
• NAGAI K, NAKAGAWA H: In: Central Regulation of Energy Metabolism with Special Reference to Circadian Rhythm. CRC Press, Orlando (1992):103–140.
   Google Scholar
• CINCOTTA AH, JONES C, YIP J et al. Ergoset® improves plasma glucose and lipid profile and body composition in weight maintained obese women. Sixteenth International Diabetes Federation Congress, Diabetologia (1997) 40 (Suppl. 1):A379.
   Google Scholar
• SCHRAN HF, BHUTA SI, SCHWARZ HJ, THORNER MO: Thepharmacokinetics of bromocriptine in man. In: Ergot Compounds, and Brain Function: Neuroendocrine and neuropsychiatric aspects. Goldstein M, Clane DB, Lieberman A, Thorner MO (Eds.) Raven Press, New York (1980125–139.
   Google Scholar
• MAURER G, SCHREIER E, DELABORDE S, LOOSLI HR, NUFER R, SHUKLA AP: Fate and disposition of bromocriptine in animals and man. I. Structure elucidation of the metabolites. Eur. J. Drug Metab. Pharmacokinet. (1982) 7:281–292.
   PubMed Web of Science ®Google Scholar
• MAURER G, SCHREIER E, DELABORDE S, NUFER R, SHUKLA AP: Fate and disposition of bromocriptine in animals and man. II. Absorption, elimination, and metabolism. Eur. J. Drug Metab. Pharmacokinet. (1983) 8:51–62.
   PubMed Web of Science ®Google Scholar
• PARKES JD: Bromocriptine. New Engl. J. Med. (1979)301:873–878.
   Google Scholar
• BURNS RS, CALNE DB: Disposition of dopaminergicergot compounds following oral administration. In: Lisuride and other dopamine agonists. Caine DB, Horowski R, Mcdonald RJ et al. (Eds.) Raven Press, New York (1983):153–160.
   Google Scholar
• VALENTE D, DELAFORGE M, URIEN S et al: Metabolicinvolvement in bromocriptine-induced prolactin inhibition in rats. J. Pharmacol Exp. Therap. (1997) 282:1418–1424.
   PubMed Web of Science ®Google Scholar
• NELSON MV, BERCHOU RC, KARETC D, LEWITT PA. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Pharmacol. Ther. (1990) 47:694–697.
   Web of Science ®Google Scholar
• CINCOTTA AH, MEIER AH, TAYLOR E, HUDSON M: Bromocriptine (Ergoset®) reduces body fat, hyperin-sulinemia, and glucose intolerance in obese subjects. Diabetes (1995) 44 (Suppl. 1):168A.
   Google Scholar
• KAMATH V, JONES CN, YIP JC: Effects of a quick - releaseform of bromocriptine (Ergoset®) of fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care (1997) 20:1697–1701
   PubMed Web of Science ®Google Scholar
• CINCOTTA AH, MEIER AH, HAAG B, RASKIN P: Bromocriptine (Ergoset0 improves glycemic control in obese-NIDDM subjects. Diabetes (1995) 44 (Suppl. 1):69A.
   Google Scholar
• FERRARI E, BOSSOLO P, MARELLI G et al: Hormonalcircadian profiles in obesity. Ann. Rev. Chronophar-macol. (1986) 3:399–402.
   Google Scholar
• CUPINSCHI G, DELAET MH, VANCAUTER E et al.: Simulta-neous study of cortisol, growth hormone, and prolactin nyctohemeral variations in normal and obese subjects: influence of prolonged fasting in obesity. Clin. Endocrinol. (1978) 9:15–26.
   PubMed Web of Science ®Google Scholar
• CREEMERS LB, ZELISSEN PMJ, VAN'T VERLATT JW, KOPPESCHAAR HPE: Prolactinoma and body weight: a retrospective study. Acta Endocrinol (1991) 125:392–396.
   PubMedGoogle Scholar
• FERRARI E, MAGRI F, GALENDA P et al.: Neuroendocrine abnormalities in primary obesity. In: Primary and Secondary Eating disorders: A Psychoneuroendocrine and Metabolic Approach (Vol. 90). Ferrari E, Bramabilla F, Solerte SB (Eds.), Pergamon, Oxford, UK (1993):287.
   Google Scholar
• LOEW DM, VAN DEUSEN EB, MEIER-RUGE W: Effects on the central nervous system. In: Ergot alkaloids and related compounds. Berde B, Schild Ho (Eds.). Springer-Venlag, New York (1978):421–532.
   Google Scholar
• DEFONZO RA: Dopamine modulation in the treatment of type 2 diabetes. Symposia on Neurohormonal modula-tion of metabolic control in type 2 diabetes at 58th annual Meeting of the American Diabetes Association.
   Google Scholar
• SCHWARTZ S: Bromocriptine (Ergoset®) improves glycemic control in type 2 diabetics on insulin. Diabetes (1999) 48 (Suppl. 1):A99.
   Google Scholar
• MEIER AH, CINCOTTA AH, LOVELL W: Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experentia (1992) 48:248–253.
   PubMedGoogle Scholar
• CINCOTTA AH, MEIER AH: Bromocriptine (Ergoset®) reduces body weight and improves glucose intoler-ance in obese subjects. Diabetes Care (1996) 19:667–670.
   PubMed Web of Science ®Google Scholar
• PELKONEN R, NIKKILA EA, GRAHNE B: Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin. Endocrinol. (04 (1982) 16:383–390.
   Google Scholar
• GUSTAFSON AB, BANASIAK MF, KALKHOFF RK, HAGEN TC, KIM HJ: Correlation of hyperprolactinemia with altered plasma insulin and glucagon; similarity to effects of late human pregnancy. J. Clin. Endocrinol Metab. (1980) 51:242–246.
   PubMed Web of Science ®Google Scholar
• SERRI 0, BEAUREGARD H, RASIO E, HARDY J: Decreased sensitivity to insulin in women with microprolac-tinomas. Fertil. Steril. (1986) 45:572–574.
   PubMed Web of Science ®Google Scholar
• ROJDMARK S, LAMMINPAA K: Does acute endogenous hyperprolactinemia affect intravenous glucose tolerance in humans? Metabolism (1984) 33:567–571.
   PubMed Web of Science ®Google Scholar
• LANDGRAF R, LANDRAF-LEURS MM, WEISSMANN A, HORL R, VON WERDER K, SCRIBA PC: Prolactin: a diabetogenic hormone. Diabetologia (1977) 13:99–104.
   PubMed Web of Science ®Google Scholar
• BARNETT AH, CHAPMAN C, GAILER K, HAYTER CJ: Effect of bromocriptine on maturity onset diabetes. Postgrad. Med. J. (1980) 56:11–14.
   PubMed Web of Science ®Google Scholar
• CINCOTTA AH, MEIER AH, CINCOTTA M Jr.: Ergoset improves glycemic control and serum lipid profile in obese NIDDM subjects on sulfonylurea. Diabetes (1997) 46\(Suppl. 1):33A.
   Google Scholar
• CINCOTTA AH, MEIER AH, CINCOTTA M Jr.: Ergoset as monotherapy, improves glycemic control in obese NIDDM subjects. Diabetes (1997) 46\(Suppl. 1): 33A.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Nutritional recommendations and principles for individuals with diabetes mellitus. Diabetes Care (1987) 10:126–132.
   PubMed Web of Science ®Google Scholar
• HARRIS JA, BENEDICT FG: A biometric study of basal metabolism in man. The Carnegie Institute, Washington, DC 1919:1–266.
   Google Scholar
• BROZEK J, GRANDE F, ANDERSON J, KEYS A: Densitrometric analysis of body composition: revision of some quantitative assumptions. Ann. N.Y. Acad. Sci. (1963) 110:113–130.
   PubMed Web of Science ®Google Scholar
• US FOOD AND DRUG ADMINISTRATION: Precose NDA 20–482. Summary Basis for Approval (1995) Washington DC.
   Google Scholar
• US FOOD AND DRUG ADMINISTRATION: Rezulin NDA 20–720. Summary Basis for Approval (1997) Washington DC.
   Google Scholar
• DEFRONZO RA, GOODMAN AM, AND THE MULTICENTER METFORMIN STUDY GROUP: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New Engl. J. Med. (1995) 333:541–9.
   PubMed Web of Science ®Google Scholar
• HADDEN D: Epidemiological assessment of macrovas-cular and microvascular complications over a wide range of glycemia. 34th Annual Meeting of the European Association for the Study of Diabetes (1998) UK-PDS: Final Results of UK Prospective Diabetes Study.
   Google Scholar
• WILSON PWF, KANNEL WB, ANDERSON KM: Lipids, glucose intolerance and vascular disease: the Framingham study. Monogr. Atheroscler. (1985) 13:1–11.
   Google Scholar
• ASSMAN G, SCHULTE H: The Prospective Cardiovas-cular Munster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J. (1988) 116:1713–1724.
   PubMed Web of Science ®Google Scholar
• ••Demonstrate that elevated plasma triglyceride levels areassociated with and/or a risk factor for cardiovascular disease.
   Google Scholar
• HOKANSON JE, AUSTIN MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk (1996) 3:213–219.
   PubMedGoogle Scholar
• ••See reference [124] for annotation.
   Google Scholar
• STAMPFER MJ, FRAUSS RM et al.: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 11:882–888.
   Google Scholar
• ••See reference [124] for annotation.
   Google Scholar
• REAVEN GM, CHEN YDI: Insulin resistance, its consequences, and coronary heart disease. Circulation (1996) 93:1780–1783.
   PubMed Web of Science ®Google Scholar
• ASSMAN G, SCHULTE H, FUNKE H, VON ECKARDSTEIN A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur. Heart J. (1998) 19(Suppl. M):M8–M14.
   Google Scholar
• ••See reference [124] for annotation.
   Google Scholar
• GAZIANO JM, HENNEKENS CH et al.: Fasting triglyc-erides, high-density lipoprotein, and risk of myocar-dial infarction. Circulation (1997) 96:2520–2525.
   PubMed Web of Science ®Google Scholar
• ••See reference [124] for annotation.
   Google Scholar
• PATSCH JR, MIESENBOCK G, HOPERWIESER T et al.: Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb. (1992) 12:1336–1345.
   PubMed Web of Science ®Google Scholar
• ••See reference [124] for annotation.
   Google Scholar
• EBENBICHLER CF et al.: Postprandial state and athero-sclerosis. Curr. Opin. Lipid. (1995) 6:286–290.
   PubMed Web of Science ®Google Scholar
• PAOLISSO G, HOWARD BV: Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet. Med. (1998) 15:360–366.
   PubMed Web of Science ®Google Scholar
• •Indicate that elevated plasma FFA can potentiate glucose and lipid abnormalities of type 2 diabetes.
   Google Scholar
• BODEN G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes (1997) 46:3–10.
   PubMed Web of Science ®Google Scholar
• •See reference [132] for annotation.
   Google Scholar
• FERRANNINI E, BARRETT EJ, BEVILACQUA S et al.: Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. (1983) 72:1737–1747.
   PubMed Web of Science ®Google Scholar
• BODEN G, CHEN X, RUIZ J et al.: Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. (1994) 93:2438–2446.
   PubMed Web of Science ®Google Scholar
• REAVEN GM, HOLLENBECK C, JENG C-Y et al.: Measure-ment of plasma glucose, free fatty acid, lactate, and insulin for 24h in patients with NIDDM. Diabetes (1988) 37:1020–1024.
   PubMed Web of Science ®Google Scholar
• LEWIS GF: Fatty acid regulation of very low density lipoprotein production. Curr. Opin. Lipid. (1997) 8:146–153.
   PubMed Web of Science ®Google Scholar
• SOWERS JR: Dopaminergic control of circadian norepi-nephrine levels in patients with essential hyperten-sion. J. Clin. Endocrinol. Metab. (1981) 53:1133–1137.
   PubMed Web of Science ®Google Scholar
• KOLLOCH R, KOBAYASHI K, DEQUATTRO V: Dopamin-ergic control of sympathetic tone and blood pressure: evidence in primary hypertension. Hypertension (1980) 2:390–394.
   PubMed Web of Science ®Google Scholar
• •Describes the dopaminergic control of sympathetic tone and hypertension.
   Google Scholar
• RACZ K, KUCHEL 0, NGUYEN TB: Bromocriptine decreases blood pressure of spontaneously hyperten-sive rats without affecting the adrenomedullary synthesis of catecholamines. j Cardiovasc. Pharmacol (1986) 8:676–680.
   PubMed Web of Science ®Google Scholar
• CLARK BJ, SCHOLTYSIK G, FLUCKIGER E: Cardiovascular actions of bromocriptine. ACTA Endocrinol. (1978) 88\(Suppl. 216):75–81.
   Google Scholar
• FALK RH, DESILVA RD, LOWN B: Reduction in vulner-ability to ventricular fibrillation by bromocriptine, a dopamine agonist. Cardiovasc. Res. (1981) 15:175–180.
   PubMed Web of Science ®Google Scholar
• •Describe the possible cardioprotective effects of bromocriptine.
   Google Scholar
• PRZUNTEK H, WELZEL D, BHIMNER E et al. Bromocriptine lessens incidence of mortality in 1-dopa-treated parkinsonian patients: prado-study discontinued. Eur.J. Gun. Pharmacol. (1992) 43:357–363.
   Web of Science ®Google Scholar
• •See reference [142] for annotation.
   Google Scholar
• GRASSI G, CATTANEO BM, SERAVALLE G et al.: Obesity and the sympathetic nervous system. Blood Pressure 5 (1996) 1 (Suppl.):43–46.
   Google Scholar
• WEIL C: The safety of bromocriptine in long-term use: a review of the literature. Curr. Med. Res. Op. (1986) 10:25–51.
   PubMed Web of Science ®Google Scholar
• •Reviews the safety of bromocriptine when used to treat a variety of medical disorders.
   Google Scholar
• WEIL C: The safety of bromocriptine in hyperprolac-tinaemic female infertility: a literature review. Curr. Med. Res. Op. (1986) 10:172–195.
   PubMed Web of Science ®Google Scholar
• BAGDADE JD, BUCHANAN WE, KUUSI T, TASKINEN M-R: Persistent abnormalities in lipoprotein composition in non-insulin dependent diabetes following intensive insulin therapy. Arteriosclerosis (1990) 10:232–239.
   PubMedGoogle Scholar
• ZHANG Y, CINCOTTA AH: Inhibitory effects of bromocriptine on vascular smooth muscle cell prolif-eration. Atherosclerosis (1997) 133:37–44.
   PubMed Web of Science ®Google Scholar
• •Describes and discusses the beneficial effects of bromocriptine on cardiovascular biology.
   Google Scholar